Copyright
©The Author(s) 2021.
World J Clin Oncol. Apr 24, 2021; 12(4): 249-261
Published online Apr 24, 2021. doi: 10.5306/wjco.v12.i4.249
Published online Apr 24, 2021. doi: 10.5306/wjco.v12.i4.249
Figure 1 Survival curves after esophagectomy with neoadjuvant chemotherapy.
A: Relapse-free survival rates of the positron emission tomography-complete metabolic response (PET-CMR) group and non-PET-CMR group (P = 0.021); B: Overall survival rates of the PET-CMR group and non-PET-CMR group (P = 0.011). PET-CMR: Positron emission tomography-complete metabolic response.
- Citation: Suzuki K, Etoh T, Shibata T, Nishiki K, Fumoto S, Ueda Y, Shiroshita H, Shiraishi N, Inomata M. Positron emission tomography complete metabolic response as a favorable prognostic predictor in esophageal cancer following neoadjuvant chemotherapy with docetaxel/cisplatin/5-fluorouracil. World J Clin Oncol 2021; 12(4): 249-261
- URL: https://www.wjgnet.com/2218-4333/full/v12/i4/249.htm
- DOI: https://dx.doi.org/10.5306/wjco.v12.i4.249